awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37268998-42581156-2695-4CE1-8C5A-0B05C4E57F71
Q37268998-42581156-2695-4CE1-8C5A-0B05C4E57F71
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37268998-42581156-2695-4CE1-8C5A-0B05C4E57F71
MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.
P2860
Q37268998-42581156-2695-4CE1-8C5A-0B05C4E57F71
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37268998-42581156-2695-4CE1-8C5A-0B05C4E57F71
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4bd1781f5caf1dd96ab6d8ec48d4d04e1be9195f
P2860
A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.